Live Breaking News & Updates on Robust Clinical Program

Stay updated with breaking news from Robust clinical program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

European Medicines Agency Grants BioMarin's Request for Accelerated Assessment of Valoctocogene Roxaparvovec for Treatment of Severe Hemophilia A

/PRNewswire/ BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) has granted its request for accelerated. ....

United States , Hank Fuchs , Debra Charlesworth , Traci Mccarty , European Commission , Drug Administration , Biomarin Pharmaceutical Inc , Worldwide Research , Exchange Commission , Prnewswire Biomarin Pharmaceutical Inc , Committee For Advanced Therapies , European Medicines Agency , Robust Clinical Program , Committee For Medicinal Products Human Use , Marin Pharmaceutical , Medicinal Products , Human Use , Advanced Therapies , Advanced Therapy Medicinal Product , Marketing Authorization Application , Biologics License Application , Regenerative Medicine Advanced Therapy , Breakthrough Therapy Designation , Orphan Drug Designation , Biomarin Pharmaceutical , Quarterly Report ,

BioMarin Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting

/PRNewswire/ BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced three oral and three poster presentations on valoctocogene roxaparvovec, an. ....

United States , Bridget Yates , Lon Cardon , Britta Handyside , Gil Farina , Debra Charlesworth , Cheng Su , Traci Mccarty , Exchange Commission , American Society Of Gene , European Medicines Agency , Biomarin Pharmaceutical Inc , Robust Clinical Program , Biomarin Pharmaceutical , American Society , Cell Therapy , Senior Vice President , Chief Scientific Strategy Officer , Investigating Mechanisms , Long Term Expression Comparison , Adeno Associated Virus , Vector Produced , Rare Genomic Integrations , Clonal Activation , Gene Specific Targeting , Marin Pharmaceutical Inc ,

BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study

BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study
Children Treated with Vosoritide Demonstrate Cumulative Height Gain of 3.52 cm at Year 2 Compared to Untreated Children
No New Safety Signals Observed
Current Regulatory Review Timelines on Track
News provided by
Share this article
Share this article
SAN RAFAEL, Calif., Dec. 21, 2020 /PRNewswire/ BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that children in the open-label long-term extension of the Phase 3 study of vosoritide, an investigational, once daily injection analog of C-type Natriuretic Peptide (CNP), maintained an increase in Annual Growth Velocity (AGV) through the second year of continuous treatment. These analyses are the result of the combination of data of the same patients enrolled in three consecutive trials. In the first trial, a run in period consisted of longitudinal measu ....

United States , United Kingdom , City Of , Melita Irving , Hank Fuchs , Asia Pacific , Debra Charlesworth , Traci Mccarty , European Commission , Drug Administration , Biomarin Pharmaceutical Inc , Exchange Commission , Worldwide Research , Prnewswire Biomarin Pharmaceutical Inc , European Medicines Agency , Robust Clinical Program , Committee For Medicinal Products Human Use , Marin Pharmaceutical , C Type Natriuretic Peptide , Annual Growth Velocity , President Worldwide Research , Clinical Geneticist , Evelina London Children , Drug User Fee Act , Medicinal Products , Human Use ,